Argent Large Cap ETF (NASDAQ:ABIG) Stock Short Interest Falls 54.3%
by Michael Walen · The Markets DailyArgent Large Cap ETF (NASDAQ:ABIG – Get Free Report) saw a large decline in short interest in October. As of October 15th, there was short interest totaling 2,725 shares, a decline of 54.3% from the September 30th total of 5,969 shares. Based on an average daily trading volume, of 4,737 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.2% of the shares of the stock are short sold.
Argent Large Cap ETF Stock Performance
Shares of NASDAQ:ABIG traded down $0.60 during trading on Friday, reaching $34.31. The company had a trading volume of 21 shares, compared to its average volume of 4,708. The firm’s fifty day moving average is $35.29 and its 200 day moving average is $33.35. The firm has a market capitalization of $60.04 million, a PE ratio of 28.52 and a beta of 0.95. Argent Large Cap ETF has a twelve month low of $28.39 and a twelve month high of $36.48.
Institutional Investors Weigh In On Argent Large Cap ETF
A hedge fund recently bought a new stake in Argent Large Cap ETF stock. YHB Investment Advisors Inc. purchased a new stake in shares of Argent Large Cap ETF (NASDAQ:ABIG – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 14,775 shares of the company’s stock, valued at approximately $521,000. YHB Investment Advisors Inc. owned 0.87% of Argent Large Cap ETF as of its most recent filing with the Securities and Exchange Commission.
Argent Large Cap ETF Company Profile
The Argent Large Cap ETF is an actively managed exchange-traded fund that seeks long-term capital appreciation by investing in approximately 30 to 35 large-cap U.S. companies. The fund focuses on “Enduring Businesses” with durable competitive advantages, consistent cash flow growth, and management teams with proven track records of value creation.
See Also
- Five stocks we like better than Argent Large Cap ETF
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
- LyondellBasell’s Dividend Looks Safer, But a New Risk Could Change That